Werbung
Werbung

IMDX

I

Insight Molecular Diagnostics Inc. Common Stock

7.45
USD
Gesponsert
-0.05
-0.73%
09. Jan., 15:58 UTC -5
Geschlossen
exchange

Nach-Markt

7.45

0.00
0.00%

IMDX Ergebnisberichte

Positives Überraschungsverhältnis

IMDX übertreffen die 15 der letzten 40Schätzungen.

38%

Nächster Bericht

Datum des nächsten Berichts
23. März 2026
Estimate for Q4 25 (Revenue/ EPS)
$295.80K
/
-$0.24
Implizierte Änderung von Q3 25 (Revenue/ EPS)
+13.77%
/
-29.41%
Implizierte Änderung von Q4 24 (Revenue/ EPS)
-80.09%
/
-87.56%

Insight Molecular Diagnostics Inc. Common Stock earnings per share and revenue

On 10. Nov. 2025, IMDX reported earnings of -0.34 USD per share (EPS) for Q3 25, missing the estimate of -0.21 USD, resulting in a -58.95% surprise. Revenue reached 260.00 tausend, compared to an expected 289.68 tausend, with a -10.25% difference. The market reacted with a +10.66% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 6 analysts forecast an EPS of -0.24 USD, with revenue projected to reach 295.80 tausend USD, implying an decrease of -29.41% EPS, and increase of 13.77% in Revenue from the last quarter.
FAQ
For Q3 2025, Insight Molecular Diagnostics Inc. Common Stock reported EPS of -$0.34, missing estimates by -58.95%, and revenue of $260.00K, -10.25% below expectations.
The stock price moved up 10.66%, changed from $6.80 before the earnings release to $7.53 the day after.
The next earning report is scheduled for 23. März 2026.
Based on 6 analysts, Insight Molecular Diagnostics Inc. Common Stock is expected to report EPS of -$0.24 and revenue of $295.80K for Q4 2025.
Scheck FXEmpire's Earnings Calendar for today's list of reporting companies.
Werbung